

April 27, 2016

Tanya Potashnik ,
Director Policy and Economic Analysis
Ginette Tognet,
Director Regulatory Affairs and Outreach
Patented Medicines Price Review Board (PMPRB)
333 Laurier Avenue West, Suite 1400
Ottawa, ON

Dear Ms. Potashnik and Ms. Tognet,

On behalf of Action Hepatitis Canada, thank you for taking the time to meet with our executive members Adam Cook and Daryl Luster on April 21. They have reported that you were very welcoming, and they were pleased to with the level of discussion they were able to have around the barrier that pricing is causing for Canadians in need of hepatitis C treatment.

We are excited to hear of your upcoming discussion paper, and appreciate being added to your mailing list for this. We look forward to assisting in making sure the patient voice is heard, in addition to the messaging from pharma and payers.

If there is any way that AHC can assist your office in the meantime, please let us know.

Sincerely,



Patricia Bacon
Chair, Action Hepatitis Canada